Evidence map›Paper›PMID 33424978›Full record

ArticleStem cells international2020

CD133 Antigen as a Potential Marker of Melanoma Stem Cells:

Tomasz Kloskowski, Joanna Jarząbkowska, Arkadiusz Jundziłł, Daria Balcerczyk, Monika Buhl, Kamil Szeliski, Magdalena Bodnar, Andrzej Marszałek, Gerard Drewa, Tomasz Drewa and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cells international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Tomasz KloskowskiChair of Urology and Andrology, Department of Regenerative Medicine, Cell and Tissue Bank, Collegium Medicum, Nicolaus Copernicus University, Sklodowskiej-Curie 9, 85-094 Bydgoszcz, Poland.ORCID https://orcid.org/0000-0001-5599-9315
Joanna JarząbkowskaChair of Urology and Andrology, Department of Regenerative Medicine, Cell and Tissue Bank, Collegium Medicum, Nicolaus Copernicus University, Sklodowskiej-Curie 9, 85-094 Bydgoszcz, Poland.
Arkadiusz JundziłłChair of Urology and Andrology, Department of Regenerative Medicine, Cell and Tissue Bank, Collegium Medicum, Nicolaus Copernicus University, Sklodowskiej-Curie 9, 85-094 Bydgoszcz, Poland.ORCID https://orcid.org/0000-0002-7743-8540
Daria BalcerczykChair of Urology and Andrology, Department of Regenerative Medicine, Cell and Tissue Bank, Collegium Medicum, Nicolaus Copernicus University, Sklodowskiej-Curie 9, 85-094 Bydgoszcz, Poland.ORCID https://orcid.org/0000-0002-9620-0773
Monika BuhlChair of Urology and Andrology, Department of Regenerative Medicine, Cell and Tissue Bank, Collegium Medicum, Nicolaus Copernicus University, Sklodowskiej-Curie 9, 85-094 Bydgoszcz, Poland.ORCID https://orcid.org/0000-0003-3010-2561
Kamil SzeliskiChair of Urology and Andrology, Department of Regenerative Medicine, Cell and Tissue Bank, Collegium Medicum, Nicolaus Copernicus University, Sklodowskiej-Curie 9, 85-094 Bydgoszcz, Poland.ORCID https://orcid.org/0000-0003-2945-8771
Magdalena BodnarDepartment of Clinical Pathomorphology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.ORCID https://orcid.org/0000-0003-3748-1058
Andrzej MarszałekDepartment of Clinical Pathology, Poznan University of Medical Sciences and Greater Poland Cancer Center, Poznan, Poland.ORCID https://orcid.org/0000-0002-6055-9151
Gerard DrewaUniversity of Bydgoszcz, Bydgoszcz, Poland.
Tomasz DrewaChair of Urology and Andrology, Department of Regenerative Medicine, Cell and Tissue Bank, Collegium Medicum, Nicolaus Copernicus University, Sklodowskiej-Curie 9, 85-094 Bydgoszcz, Poland.ORCID https://orcid.org/0000-0002-5529-4320
Marta PokrywczyńskaChair of Urology and Andrology, Department of Regenerative Medicine, Cell and Tissue Bank, Collegium Medicum, Nicolaus Copernicus University, Sklodowskiej-Curie 9, 85-094 Bydgoszcz, Poland.ORCID https://orcid.org/0000-0003-3259-087X
Nicolaus Copernicus University · PLPoznan University of Medical Sciences · PLUniversity of Bydgoszcz · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melanoma is the most dangerous type of skin cancer. Cancer stem cells (CSCs) are suspected to be responsible for the cancer recurrence and in the consequence for cancer therapy failure. CD133 is a potential marker for detection of melanoma CSCs. Experiments were performed on the B16-F10 mouse melanoma cell line. CD133+ cells were isolated using an immunomagnetic cell sorting technique. After isolation proliferative and clonogenic potential of CD133+, CD133- and CD133+/- were evaluated. The potential of CD133+ and CD133- cells for tumor induction was conducted on C57BL/6J mouse model. Three different cell quantities (100, 1000, 10000) were tested. Tumor morphology, number of mitoses, and tumor necrosis area were analyzed. Average 0.12% CD133+ cells were isolated. Compared to CD133- and unsorted CD133+/- cells, CD133+ cells were characterized by the higher proliferative and clonogenic potential. These properties were not confirmed

Identifiers

PMID33424978
PMCPMC7774302
OpenAlexW3113598422

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.